SENSEX    38040.57       15.12    |    NIFTY    11214.05       13.90 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
COMMODITIES
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Hot Pursuit
Scrips, which has significant changes during the market hours for last one week.
Dr Lal Path Labs Q1 PAT drops 52% to Rs 28 cr
01-Aug-20   12:49 Hrs IST

Consolidated profit before tax (PBT) dropped 57.4% to Rs 38.10 crore in Q1 June 2020 as against Rs 89.40 crore in Q1 June 2019. Current tax expense for the quarter tumbled 64.5% at Rs 12.10 crore as against Rs 34.10 crore in Q1 June 2019. The result was declared during market hours yesterday, 31 July 2020.

Normalised EBITDA skid 45.5% to Rs 54 crore in Q1 FY21 as against Rs 99 crore in Q1 FY20. Normalised EBITDA margin stood at 20.3% in Q1 FY21 as compared to 29.5% in Q1 FY20.

During the quarter, patient volumes declined 28.4% Y-o-Y (year-on-year) to 3.5 million. Cash, FDs and Mutual Funds (MF) at Rs 759.80 crore as on 30 June 2020 as against Rs 744.30 crore as on 31 Mar 2020, registering a growth of 2.08% Q-o-Q (quarter-on-quarter). The COVID-19 outbreak continues to adversely impact patient volumes in the month of April 2020 and May 2020. However, the business momentum improved in June 2020. COVID-19 testing contributed significantly to the turnover in Q1.

Commenting on the Q1 result announcement, (Hony) Brig. Dr. Arvind Lal, the executive chairman of Dr Lal Path Labs, has said that: This was a difficult quarter, not just for Dr Lal Pathlabs, but for the entire nation and the economy. Business was impacted adversely, with volumes getting hit. However, we are confident of things returning to normal and the business performance getting back on track in some time post normalization. With the shift in trend from unorganized to organized players and our robust hub and spoke model, this will be achieved as we get back to providing accurate diagnostics services at affordable prices to our patients.

Bharath Uppiliappan, the chief executive officer (CEO) of Dr Lal Path Labs, has said that: While Q1 FY21 has been extremely challenging for us, we have started to witness improvement in patient volumes as the lockdown is being relaxed. We are seeing good traction in the month of June over last year. We are focused on improving our service levels and test offerings to our patients and clients, enabling business to recover as fast as possible.

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. As on 31 March 2020 the company has 216 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,095 Patient Service Centers (PSCs) and 6,995 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Shares of Dr Lal PathLabs rose 0.41% to Rs 1,888.85 on BSE on Friday. The stock traded in the range of Rs 1,862.60 to Rs 1,965 on that day.

On the technical front, the stock's RSI (relative strength index) stood at 59.422 as on Friday, 31 July 2020. The RSI oscillates between zero and 100. Traditionally, the RSI is considered overbought when above 70 and oversold when below 30.

On Friday, the stock was trading above its 50-day moving average (DMA) placed at 1,691.01 and its 200-day moving average (DMA) placed at 1,590.03.

Powered by Capital Market - Live News

Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.90 88.63 1.19
United Kingdom (GBP) 1.11 1.00 98.21 1.31
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.84 0.76 74.70 1.00
Commodities << ALL Commodities
GOLDAHMD55922400
SILVERAHMD73755871
CRUDEOILMUMBAI3140-24
COPPERMUMBAI509.80.10
 Market News << ALL News
   Disclaimer   |   BSE Disclosure  |   Privacy Policy   |   Investor Protection   |   Inactive Account
Feedback   |   PMLA Policy   |   Risk Management Policy   |   Insider Trading   
  
   Investor Grivenances   |   Investor Complaints   |   Rules And Regulations   |   Broker Norms   |   Terms of Use SEBI Registration No : INZ000267132   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2015 certified)